Selvita S.A.

Zadzwoń Wskazówki dojazdu Strona internetowa Kontakt: firmę

Selvita S.A. Integrated Drug Discovery | Drug Development | Contract Research The Company’s research sites are in Krakow (HQ), Poznan, Poland, and Zagreb, Croatia.

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. Selvita provides comprehensive solutions supporting Clients and their drug discovery projects, across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development. On top of that Selvita also offers analytical support of drug development and contract testing studies. Selvita, established in 2007, operates globally with over 900 highly qualified employees, of which over 40% hold a PhD degree. The international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Ardigen, a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine, is part of Selvita Group portfolio of companies. Selvita is listed on the Warsaw Stock Exchange (WSE: SLV).

We're excited to inform that we’re expanding our collaboration with https://eu1.hubs.ly/H0z4kB30.Since July 2025, our ch...
14/10/2026

We're excited to inform that we’re expanding our collaboration with https://eu1.hubs.ly/H0z4kB30.

Since July 2025, our chemists have used ChemAIRS®, https://eu1.hubs.ly/H0z4kB30’s AI-powered retrosynthesis platform, to support synthetic route design in drug discovery projects. Now we are extending its use with access to four additional modules: Retrosynthesis, Condition Search, Impurity Prediction and Quotation.

ChemAIRS® sits alongside our internal AI/ML models and workflows, across medicinal, computational and process chemistry, helping our teams explore and compare potential routes and assess feasibility earlier, so resources go to the most promising approaches.

𝐇𝐨𝐰 𝐜𝐚𝐧 𝐞𝐚𝐫𝐥𝐲 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭 𝐡𝐞𝐥𝐩 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐥𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐚𝐧𝐝 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐦𝐨𝐫𝐞 𝐜𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐭 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐥𝐞𝐚𝐝 𝐬𝐞𝐥...
13/10/2026

𝐇𝐨𝐰 𝐜𝐚𝐧 𝐞𝐚𝐫𝐥𝐲 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭 𝐡𝐞𝐥𝐩 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐥𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐚𝐧𝐝 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐦𝐨𝐫𝐞 𝐜𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐭 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐥𝐞𝐚𝐝 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧?

In our latest blog post, our experts Andrzej Dubiel and Małgorzata Rydzy share a real-world case study showing how Selvita evaluated 800 IgG1 monoclonal antibodies in just eight weeks, using a stepwise screening strategy to identify potential development risks and select 10 promising leads.

Discover how integrating multiple experimental readouts can support data-driven GO/NO-GO decisions and help reduce downstream development risks.

Read the full case study: https://eu1.hubs.ly/H0z2yT-0

𝐈𝐧 𝐁𝐚𝐬𝐞𝐥 𝐟𝐨𝐫 𝐅𝐞𝐬𝐭𝐢𝐯𝐚𝐥 𝐨𝐟 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬?
Andrzej is attending the event and will present “Developability of Antibodies: Challenges and Future Directions” on 14 October at 5:10 PM in Theatre 8. If you're at the event, don't miss the opportunity to hear his insights!

𝐂𝐚𝐧 𝐏𝐁𝐏𝐊 𝐦𝐨𝐝𝐞𝐥𝐢𝐧𝐠 𝐡𝐞𝐥𝐩 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬 𝐦𝐚𝐤𝐞 𝐛𝐞𝐭𝐭𝐞𝐫 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐚𝐥 𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐞𝐚𝐫𝐥𝐲 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲?In their new article...
12/10/2026

𝐂𝐚𝐧 𝐏𝐁𝐏𝐊 𝐦𝐨𝐝𝐞𝐥𝐢𝐧𝐠 𝐡𝐞𝐥𝐩 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬 𝐦𝐚𝐤𝐞 𝐛𝐞𝐭𝐭𝐞𝐫 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐚𝐥 𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐞𝐚𝐫𝐥𝐲 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲?
In their new article, our experts Simone Esposito and David Cebrián explore how physiologically based pharmacokinetic (PBPK) modeling can help researchers better understand complex drug disposition and support informed decision-making in early drug discovery, particularly for compounds that challenge traditional optimization approaches.
They outline a practical workflow combining early in vivo data, literature-derived reference compounds, and sensitivity analysis to identify key drivers of drug exposure, prioritize experiments, and inform medicinal chemistry decisions.

Find the link to the article on our website: https://eu1.hubs.ly/H0z0V180

Explore more from the authors:
Webinar "PROTACs at Target: PBPK-PD Tools Linking Exposure to Effect": https://eu1.hubs.ly/H0z0V420
Previous publication "Translational PBPK/PD Modeling in Drug Discovery: A CRO Perspective": https://eu1.hubs.ly/H0z0V430

Thank you to everyone who visited Selvita at CPHI Milan 2026. It was a pleasure meeting so many of you, learning more ab...
09/10/2026

Thank you to everyone who visited Selvita at CPHI Milan 2026.

It was a pleasure meeting so many of you, learning more about your projects and discussing analytical development, CMC challenges and the next steps in drug development.

We also enjoyed the coffee breaks, informal conversations and moments shared at our booth. ☕️

If we didn't get a chance to connect, or if you'd like to continue a conversation from the show, we'd be happy to hear from you.

📩 Get in touch: https://eu1.hubs.ly/H0y-4Km0

Thank you for being part of the event with us. See you at the next one!

Biologics rarely have a straight road from first hit to patient, and Festival of Biologics in Basel brings together ever...
08/10/2026

Biologics rarely have a straight road from first hit to patient, and Festival of Biologics in Basel brings together everyone who works on every stretch of it, from discovery to manufacturing.

Selvita will be there on several fronts, and one of them is a talk we are especially looking forward to. On 14 October at 5:10 PM in Theatre 8, Andrzej Dubiel will present "Developability of Antibodies: Challenges and Future Directions".

Developability is where a promising molecule meets reality: stability, solubility, aggregation, and manufacturability. Andrzej will explain why early screening often fails to predict later behaviour and why long-term stability is so hard to predict. The talk will also look ahead, toward standardized high-throughput assays and AI-driven tools, with practical insights from a CRO perspective.

The rest of the Selvita team will be in Basel as well. Edyta Żyła will present a poster, "From Difficult to Deliverable: Strategic Approaches That Move Challenging Proteins Forward", showing how tailoring the approach to each protein, from conjugation to membrane protein purification and capsid assembly, delivers high-quality materials for biologics research. Elżbieta Plebanek and Irwin Matyjaszczyk, a scientist with hands-on antibody experience, are happy to talk about projects and challenges.

Whether your project is at the very beginning or already heading toward the clinic, come and find us in Basel, and stop by Andrzej’s talk at Theatre 8 on 14 October at 5:10 PM.

Greetings from BioJapan 2026!Our team is enjoying some great conversations here. Stop by booth C-69 to meet Nobuhisa, Mo...
07/10/2026

Greetings from BioJapan 2026!

Our team is enjoying some great conversations here. Stop by booth C-69 to meet Nobuhisa, Monika, Martina and Maciej, they'd love to talk about your projects, and the science behind them.

A little look at what's happening at our booth at CPHI Milan! 📸If you're here, come and find us at booth 10G29, Hall H10...
06/10/2026

A little look at what's happening at our booth at CPHI Milan! 📸

If you're here, come and find us at booth 10G29, Hall H10.

• Meet our experts and discuss your analytical and development challenges
• Stop by for a coffee
• Pick up some Selvita goodies
• Capture a memory with our Instax

There's still time to stop by, meet our team and talk about your next development project.

See you soon!

Transporter data are rarely available early in discovery, yet for ECCS class 1B/3B compounds - acids and zwitterions - t...
02/10/2026

Transporter data are rarely available early in discovery, yet for ECCS class 1B/3B compounds - acids and zwitterions - they often drive clearance and distribution. The poster, "A Pragmatic PBPK-Driven Strategy for ECCS Class 1B/3B Compounds" presents a tiered framework for exactly this challenge: practical clearance inputs, tested translational assumptions, and a clear signal for when deeper mechanistic work is worth it.

Co-authored by David Cebrian and Simone Esposito, it will be presented at the DMDG-GMP-SPS Joint Meeting 2026 in Prague (5–7 October), where this year's programme spans advanced modelling, AI, novel modalities, and translational PK science. Petra Mišetić and Renata Buđa will also be on site. Stop by and discuss ADME, (PB)PK/PD modelling, and translational approaches to human PK and dose prediction.

𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐢𝐧𝐭𝐫𝐢𝐧𝐬𝐢𝐜𝐚𝐥𝐥𝐲 𝐝𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐞𝐝 𝐩𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐬𝐨 𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥𝐥𝐲 𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐥𝐞 𝐜𝐚𝐧 𝐚𝐥𝐬𝐨 𝐦𝐚𝐤𝐞 𝐭𝐡𝐞𝐦 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫𝐥𝐲 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐭𝐨 𝐰𝐨...
01/10/2026

𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐢𝐧𝐭𝐫𝐢𝐧𝐬𝐢𝐜𝐚𝐥𝐥𝐲 𝐝𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐞𝐝 𝐩𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐬𝐨 𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥𝐥𝐲 𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐥𝐞 𝐜𝐚𝐧 𝐚𝐥𝐬𝐨 𝐦𝐚𝐤𝐞 𝐭𝐡𝐞𝐦 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫𝐥𝐲 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐭𝐨 𝐰𝐨𝐫𝐤 𝐰𝐢𝐭𝐡 𝐢𝐧 𝐭𝐡𝐞 𝐥𝐚𝐛.
Unlike conventional globular proteins, intrinsically disordered proteins (IDPs) and regions (IDRs) lack a single, stable three-dimensional structure. Their unique properties enable dynamic interactions involved in numerous cellular processes — but can also contribute to degradation, aggregation, and unexpected behavior during recombinant protein production, purification, and analysis.

In our latest blog article, Monika Janczak, our protein sciences expert, explores the distinctive properties of IDPs and what they mean from a practical protein production perspective.
The article also presents 𝐭𝐰𝐨 𝐜𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 showing how target-specific optimization of construct design, expression, and purification conditions can help overcome challenges associated with aggregation- and degradation-prone IDPs.

Read the full article to learn how a tailored approach can support the production of stable, high-quality IDP samples for downstream studies: https://eu1.hubs.ly/H0yL6Fb0

CPHI Milan is just one week away!Our drug development experts are heading to Milan, and we’re looking forward to meeting...
30/09/2026

CPHI Milan is just one week away!

Our drug development experts are heading to Milan, and we’re looking forward to meeting you there.

Meet our team at our booth , Hall H10

We’ll be there to discuss analytical strategy, complex molecules and the challenges that can slow a development program down.

Whether you’re working on an early-stage program or preparing for late-stage and commercial development, come by and let’s talk about the analytical challenges behind your project.

Still haven’t booked a meeting? There’s still time: https://eu1.hubs.ly/H0yJCL40

We can’t wait to meet you in Milan!

Adres

Bobrzyńskiego 14
Kraków
30-348

Telefon

+48122974700

Strona internetowa

Powiadomienia

Bądź na bieżąco: wyślemy Ci e-mail, gdy Selvita S.A. opublikuje nowości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu, a subskrypcję możesz anulować w dowolnym momencie.

Kontakt: Firmę

Wyślij wiadomość do Selvita S.A.:

Skróty

Udostępnij